Specific binding sites for insulin and insulin-like growth factor I in human endometrial cancer

Nagamani, Manubai; Stuart, Charles Alexander; Dunhardt, Patricia A.; Doherty, M.G.

doi:10.1016/0002-9378(91)90047-u

Cited by 45 publications

(21 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Lastly, increased concentrations of plasma insulin in patients with endometrial cancer (324) and insulin-binding sites have been found in the endometrial stroma of premenopausal women and women with endometrial cancer (323). Thus, compensatory hyperinsulinemia could exert a deleterious effect on endometrium acting on specific insulin-binding sites exerting a mitogenic effect.…”

Section: B Cancer Implicationsmentioning

confidence: 99%

Evidence-Based and Potential Benefits of Metformin in the Polycystic Ovary Syndrome: A Comprehensive Review

et al. 2008

View full text Add to dashboard Cite

Metformin is an insulin sensitizer widely used for the treatment of patients affected by type 2 diabetes mellitus. Because many women with polycystic ovary syndrome (PCOS) are insulin resistant, metformin was introduced in clinical practice to treat these patients also. Moreover, metformin's effect has other targets beside its insulin-sensitizing action. The present review was aimed at describing all evidence-based and potential uses of metformin in PCOS patients. In particular, we will analyze the uses of metformin not only for the treatment of all PCOS-related disturbances such as menstrual disorders, anovulatory infertility, increased abortion, or complicated pregnancy risk, hyperandrogenism, endometrial, metabolic and cardiovascular abnormalities, but also for the prevention of the syndrome. (Endocrine Reviews 30: 1-50, 2009)

show abstract

Section: B Cancer Implicationsmentioning

confidence: 99%

Evidence-Based and Potential Benefits of Metformin in the Polycystic Ovary Syndrome: A Comprehensive Review

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Regardless, statistically significantly higher receptor binding affinity was found in EC tissues as compared to healthy endometrium. Also, IGF-1R binding affinity was proven to increase in response to decreasing tumor differentiation [23,25]. Additionally, tamoxifen, which is used in breast cancer therapy and which is a risk factor for the development of EC, has been demonstrated to lead to EC cell proliferation by inducing IGF-1R phosphorylation [26].…”

Section: Hypothetical Role Of Igf-1 In the Biology Of Endometrial Cancermentioning

confidence: 99%

Does IGF-1 play a role in the biology of endometrial cancer?

Majchrzak-Baczmańska

Malinowski

2016

Ginekol Pol

View full text Add to dashboard Cite

Insulin-like growth factor 1 (IGF-1) is a mitogen which plays a key role in regulating cell proliferation, differentiation, and apoptosis. It belongs to the family of proteins also composed of insulin-like growth factor 2 (IGF-2), two types of membrane receptors (IGF-1R and IGF-2R), 6 binding proteins (IGFBP 1-6), hydrolyzing proteases, and reactive molecules binding proteins, which regulate the activity of growth factors. Disturbances in the functioning of IGFBP/IGF/1GF1R can lead to induction of carcinogenesis, which has been demonstrated in breast, prostate or colon cancers. Findings evaluating the role of IGF-1 in endometrial cancer biology are ambiguous and contradictory. Therefore, in the present study, we analyzed the role of IGF-1 in the process of carcinogenesis of endometrial cancer, based on the available literature.

show abstract

“…Diabetes mellitus is linked with EC and even in women receiving exogenous oestrogens, women with diabetes are at higher risk (Harding et al, 2014); higher insulin levels have been found in postmenopausal women (who have low oestrogen levels) with EC (Ayabe et al, 1997, Nagamami and Stuart, 1998); insulin and insulin like growth factor (IGF) receptors have been identified in both normal and malignant (Ayabe et al, 1997) endometrium; Insulin, IGF 1 and IGF 2 have been shown to have a mitogenic effect on endometrial cells in-vitro with type I IGF receptor mRNA over-expressed in EC (Nagamani 1991) and the number of type I IGF receptors present has been shown to positively correlate with the histological grade of EC (Nagamani et al 1991, Talavera et al 1990. Genomic (Pillay et al, 2005) and proteomic (Galazis et al, 2013) approaches have also identified potential new genes and proteins which might explain link between PCOS and EC and could up-regulate genes with the insulin signaling pathway in PCOS.…”

Section: Introductionmentioning

confidence: 99%

Up-regulation of genes involved in the insulin signalling pathway (IGF1, PTEN and IGFBP1) in the endometrium may link polycystic ovarian syndrome and endometrial cancer

Shafiee

Seedhouse

Mongan

et al. 2016

Molecular and Cellular Endocrinology

View full text Add to dashboard Cite

Specific binding sites for insulin and insulin-like growth factor I in human endometrial cancer

Cited by 45 publications

References 20 publications

Evidence-Based and Potential Benefits of Metformin in the Polycystic Ovary Syndrome: A Comprehensive Review

Evidence-Based and Potential Benefits of Metformin in the Polycystic Ovary Syndrome: A Comprehensive Review

Does IGF-1 play a role in the biology of endometrial cancer?

Up-regulation of genes involved in the insulin signalling pathway (IGF1, PTEN and IGFBP1) in the endometrium may link polycystic ovarian syndrome and endometrial cancer

Contact Info

Product

Resources

About